A Phase 3 interventional study of RO7496998 and Placebo in COVID-19, sponsored by Hoffmann-La Roche. Terminated at 50 sites in 12 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2024-01-05.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies in COVID-19 with a site in Japan — 10 open to participants now, 11 under way, 8 of them phase 3. COVID-19 · Japan.
Among the 75 studies in COVID-19 with a site in Japan, this one is the 41st largest by enrollment of the 59 interventional ones that give a count, is one of 22 that started in 2021, is one of 34 in phase 3, and was the 36th registered.
7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.
Browse COVID-19 studies →10 of the 75 studies in COVID-19 with a site in Japan are open now. Recruiting first, the newest first:
Shionogi · Sites in Japan, United States, Bulgaria
Ages 12+
Shionogi · Sites in Japan
Ages 12–74
Pfizer · Sites in Japan, United States, Argentina and 15 more countries
Ages 18+
Pfizer · Sites in Japan, United States, Argentina and 16 more countries
Ages 12+
Merck Sharp & Dohme LLC · Sites in Japan, United States, Argentina and 21 more countries
Ages 18+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 19 · Phase 3 40 · Phase 4 1
First in 2016; this study’s year is marked. 22 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 216 is above the median of 102 across 4,366 interventional studies indexed under COVID-19.
Median enrollment 602 across the 59 interventional studies, 3,346 across the 15 observational. Of the 58 that completed or were terminated, 36 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
61 of 75 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Hoffmann-La Roche has 9 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
5 of the studies in COVID-19 with a site in Japan that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07746544Phase 3ShionogiStudy of Secutrelvir in Participants With COVID-19 | 2027-07-31 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT07739446Chiba UniversityEffect of Surgical Masks in Preventing Acute Respiratory Infections | 2027-03 |
Add all 5 to your calendar (.ics) → With an account.
Among the 75 studies in COVID-19 with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy, safety, antiviral activity, and pharmacokinetics of study drug RO7496998 (AT-527) compared to placebo in non-hospitalized adult and adolescent participants with mild to moderate coronavirus disease 2019 (COVID-19) in the outpatient setting.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The dose and regimen of the placebo will match that of AT-527.
Drug: Placebo
Orally administered, 550 mg twice daily (BID) for 5 days
Drug: RO7496998
275 mg tablets
Also known as: AT-527
Matching tablets
Time to Alleviation or Improvement of COVID-19 Symptoms (21.5 Hours)
COVID-19 symptoms will be evaluated using the COVID-19 Symptom Diary (questions 1-12). The severity of each COVID-19 symptom will be recorded on a Likert scale (i.e none/mild/moderate/severe). The time to alleviation or improvement of COVID-19 symptoms is defined as follows: for new symptoms, it is defined as the length of time taken from randomization to the point at which a Score of 0 or 1 has been maintained for a duration of at least 21.5 hours. For preexisting symptoms, it is defined as the time from randomization to when a patient's symptoms have been maintained or improved (requires at least a single category improvement from baseline on the COVID-19 Symptom Diary Likert scale) for a duration of 21.5 hours.
Time frame: Up to 29 days
Time to Alleviation or Improvement of COVID-19 Symptoms (43 Hours)
COVID-19 symptoms will be evaluated using the COVID-19 Symptom Diary (questions 1-12). The severity of each COVID-19 symptom will be recorded on a Likert scale (i.e none/mild/moderate/severe). The time to alleviation or improvement of COVID-19 symptoms is defined as follows: for new symptoms, it is defined as the length of time taken from randomization to the point at which a Score of 0 or 1 has been maintained for a duration of at least 43 hours. For preexisting symptoms, it is defined as the time from randomization to when a patient's symptoms have been maintained or improved (requires at least a single category improvement from baseline on the COVID-19 Symptom Diary Likert scale) for a duration of 43 hours.
Time frame: Up to 29 days
Time to Alleviation of COVID-19 Symptoms (21.5 Hours)
Time from randomization to the point at which the following criterion is met and maintained for at least 21.5 hours. - Score of 0 or 1 on Items 1-12 of the COVID-19 Symptom Diary.
Time frame: Up to 29 days
Time to Alleviation of COVID-19 Symptoms (43 Hours)
Time from randomization to the point at which the following criterion is met and maintained for at least 43 hours. - Score of 0 or 1 on Items 1-12 of the COVID-19 Symptom Diary.
Time frame: Up to 29 days
Time to One-Category Improvement of Baseline Presenting COVID-19 Symptoms
Time from randomization to the point at which symptoms (Items 1-12 of the COVID-19 Symptom Diary) have improved by at least one category from baseline on the COVID-19 Symptom Diary Likert scale, maintained for at least 21.5 hours.
Time frame: Up to 29 days
Time to Alleviation of Individual Symptoms
Time from randomization to the point at which the following criterion is met and maintained (for each individual symptom) for at least 21.5 hours. - Score of 0 or 1 for Items 1-14 of the COVID-19 Symptom Diary
Time frame: Up to 29 days
Percentage of Participants Requiring Hospitalization for COVID-19
Hospitalizations for COVID-19 are defined as SAEs for which the investigator has cited that the suspected cause was the disease under study and where there is a non-missing hospital admission date.
Time frame: Up to Day 33 visit
Percentage of Participants With Greater Than or Equal to 1 COVID-19 Related Medically Attended Visit
Medically attended visit is defined as hospitalization, emergency room (ER) visit, urgent care visit, physician's office visit, or telemedicine visit, with the primary reason for the visit being COVID-19.
Time frame: Up to Day 33 visit
Duration of Fever
Time to return to an afebrile state (temperature ≤ 37.5°C) maintained for at least 21.5 hours.
Time frame: Up to 29 days
Percentage of Participants With COVID-19 Related Complications
COVID-related complications are defined as death, hospitalization, pneumonia, sepsis, coagulopathy, pericarditis/myocarditis and cardiac failure. Pneumonia, acute respiratory failure, sepsis, coagulopathy, pericarditis/myocarditis, and cardiac failure were adjudicated per blinded manual medical review of events by an internal adjudication team before study readout.
Time frame: Up to Day 33 visit
Percentage of Participants With Any Post-Treatment Infection
Post-treatment infections were defined as any treatment-emergent adverse event with a primary system organ class of infections and infestations.
Time frame: Up to Day 33 visit
Change From Baseline in the Amount of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus RNA
SARS-CoV-2 virus RNA will be measured by reverse-transcriptase quantitative polymerase chain reaction (RT-qPCR)
Time frame: Baseline and on Days 3, 5, 7 and 14
Time to Cessation of SARS-CoV-2 Viral Shedding
Defined as time from randomization to the first time when a negative qualitative virus RNA by RT-PCR test result is obtained.
Time frame: Up to 14 days
Percentage of Participants Positive for SARS-CoV-2 Virus RNA at Specified Timepoints
Defined as percentage of participants with a positive qualitative virus RNA by RT-PCR.
Time frame: Baseline and on Days 3, 5, 7 and 14
Area Under the Curve (AUC) in the Amount of SARS-CoV-2 Virus RNA
Time frame: Day 1 prior to dosing, Day 3, Day 5, Day 7 and Day 14
Percentage of Participants With Adverse Events (AEs)
Time frame: Up to Day 33 visit
Plasma Concentration of AT-511 at Specified Timepoints
AT-511 is the free base form of RO7496998 (AT-527).
Time frame: Up to 7 days
Plasma Concentration of AT-551 at Specified Timepoints
AT-511 is the free base form of RO7496998 (AT-527). Major metabolites are AT-551, AT-229, and AT-273 (a surrogate for the intracellular concentration of the active triphosphate metabolite AT-9010)
Time frame: Up to 7 days
Plasma Concentration of AT-229 at Specified Timepoints
AT-511 is the free base form of RO7496998 (AT-527). Major metabolites are AT-551, AT-229, and AT-273 (a surrogate for the intracellular concentration of the active triphosphate metabolite AT-9010)
Time frame: Up to 7 days
Plasma Concentration of AT-273 at Specified Timepoints
AT-511 is the free base form of RO7496998 (AT-527). Major metabolites are AT-551, AT-229, and AT-273 (a surrogate for the intracellular concentration of the active triphosphate metabolite AT-9010)
Time frame: Up to 7 days
Participants were non-hospitalized, with mild to moderate COVID-19, with or without risk factors for severe disease.
| Milestone | Placebo | RO7496998 (AT-527) |
|---|---|---|
| Started | 73 | 143 |
| Received treatment | 71 | 141 |
| Completed | 68 | 138 |
| Not completed | 5 | 5 |
| Withdrew: Withdrawal by subject | 3 | 3 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Adverse event | 2 | 1 |
COVID-19 symptoms will be evaluated using the COVID-19 Symptom Diary (questions 1-12). The severity of each COVID-19 symptom will be recorded on a Likert scale (i.e none/mild/moderate/severe). The time to alleviation or improvement of COVID-19 symptoms is defined as follows: for new symptoms, it is defined as the length of time taken from randomization to the point at which a Score of 0 or 1 has been maintained for a duration of at least 21.5 hours. For preexisting symptoms, it is defined as the time from randomization to when a patient's symptoms have been maintained or improved (requires at least a single category improvement from baseline on the COVID-19 Symptom Diary Likert scale) for a duration of 21.5 hours.
| hours | Placebo | RO7496998 (AT-527) |
|---|---|---|
| Time to Alleviation or Improvement of COVID-19 Symptoms (21.5 Hours) | 73.7 (47.1 to 105.8) | 94.5 (68.1 to 131.7) |
COVID-19 symptoms will be evaluated using the COVID-19 Symptom Diary (questions 1-12). The severity of each COVID-19 symptom will be recorded on a Likert scale (i.e none/mild/moderate/severe). The time to alleviation or improvement of COVID-19 symptoms is defined as follows: for new symptoms, it is defined as the length of time taken from randomization to the point at which a Score of 0 or 1 has been maintained for a duration of at least 43 hours. For preexisting symptoms, it is defined as the time from randomization to when a patient's symptoms have been maintained or improved (requires at least a single category improvement from baseline on the COVID-19 Symptom Diary Likert scale) for a duration of 43 hours.
| hours | Placebo | RO7496998 (AT-527) |
|---|---|---|
| Time to Alleviation or Improvement of COVID-19 Symptoms (43 Hours) | 79.6 (55.7 to 108.2) | 109.5 (83.8 to 147.5) |
Time from randomization to the point at which the following criterion is met and maintained for at least 21.5 hours. - Score of 0 or 1 on Items 1-12 of the COVID-19 Symptom Diary.
| hours | Placebo | RO7496998 (AT-527) |
|---|---|---|
| Time to Alleviation of COVID-19 Symptoms (21.5 Hours) | 73.7 (47.1 to 105.8) | 94.5 (68.1 to 131.7) |
Time from randomization to the point at which the following criterion is met and maintained for at least 43 hours. - Score of 0 or 1 on Items 1-12 of the COVID-19 Symptom Diary.
| hours | Placebo | RO7496998 (AT-527) |
|---|---|---|
| Time to Alleviation of COVID-19 Symptoms (43 Hours) | 79.6 (55.7 to 108.2) | 109.5 (83.8 to 147.5) |
Time from randomization to the point at which symptoms (Items 1-12 of the COVID-19 Symptom Diary) have improved by at least one category from baseline on the COVID-19 Symptom Diary Likert scale, maintained for at least 21.5 hours.
| hours | Placebo | RO7496998 (AT-527) |
|---|---|---|
| Time to One-Category Improvement of Baseline Presenting COVID-19 Symptoms | 70.9 (41.8 to 91.8) | 81.5 (60.5 to 119.9) |
Time from randomization to the point at which the following criterion is met and maintained (for each individual symptom) for at least 21.5 hours. - Score of 0 or 1 for Items 1-14 of the COVID-19 Symptom Diary
| hours | Placebo | RO7496998 (AT-527) |
|---|---|---|
| Nasal Congestion or Runny Nose | 36.4 (23.4 to 60.6) | 37.3 (23.4 to 57.6) |
| Sore Throat | 45.6 (23.4 to 75.1) | 33.2 (20.9 to 54.3) |
| Cough | 37.6 (26.8 to 118.7) | 49.5 (28.4 to 106.4) |
| Shortness of Breath | 24.0 (11.8 to 106.8) | 47.5 (32.4 to 96.8) |
| Muscle or Body Aches | 35.3 (14.3 to 59.4) | 44.9 (33.1 to 53.0) |
| Fatigue | 66.6 (36.5 to 118.9) | 61.3 (47.1 to 108.1) |
| Headache | 23.2 (14.5 to 41.8) | 41.4 (24.4 to 59.5) |
| Chills/Sweats | 36.0 (22.5 to 57.6) | 39.0 (28.4 to 50.5) |
| Feeling Hot or Feverish | 24.6 (16.4 to 66.7) | 36.2 (19.7 to 61.4) |
| Nausea | 31.4 (11.1 to NA) | 43.5 (22.6 to 73.4) |
| Vomiting | 20.1 (16.4 to NA) | 33.0 (NA to NA) |
| Diarrhea | 17.6 (14.9 to 73.6) | 66.7 (19.8 to 107.2) |
| Sense of Smell | 132.6 (84.3 to 229.0) | 104.9 (72.6 to 206.0) |
| Sense of Taste | 128.9 (84.3 to 202.2) | 155.7 (52.5 to 371.7) |
Hospitalizations for COVID-19 are defined as SAEs for which the investigator has cited that the suspected cause was the disease under study and where there is a non-missing hospital admission date.
| percentage of participants | Placebo | RO7496998 (AT-527) |
|---|---|---|
| Percentage of Participants Requiring Hospitalization for COVID-19 | 10.0 (1.25 to 18.75) | 2.9 (0.00 to 6.51) |
Medically attended visit is defined as hospitalization, emergency room (ER) visit, urgent care visit, physician's office visit, or telemedicine visit, with the primary reason for the visit being COVID-19.
| percentage of participants | Placebo | RO7496998 (AT-527) |
|---|---|---|
| Percentage of Participants With Greater Than or Equal to 1 COVID-19 Related Medically Attended Visit | 14.3 (4.20 to 24.37) | 10.2 (4.05 to 16.38) |
Time to return to an afebrile state (temperature ≤ 37.5°C) maintained for at least 21.5 hours.
| hours | Placebo | RO7496998 (AT-527) |
|---|---|---|
| Duration of Fever | 47.3 (12.6 to 82.2) | 55.7 (25.9 to 96.4) |
COVID-related complications are defined as death, hospitalization, pneumonia, sepsis, coagulopathy, pericarditis/myocarditis and cardiac failure. Pneumonia, acute respiratory failure, sepsis, coagulopathy, pericarditis/myocarditis, and cardiac failure were adjudicated per blinded manual medical review of events by an internal adjudication team before study readout.
| percentage of participants | Placebo | RO7496998 (AT-527) |
|---|---|---|
| Percentage of Participants With COVID-19 Related Complications | 10.0 (1.25 to 18.75) | 4.4 (0.10 to 8.66) |
Post-treatment infections were defined as any treatment-emergent adverse event with a primary system organ class of infections and infestations.
| percentage of participants | Placebo | RO7496998 (AT-527) |
|---|---|---|
| Percentage of Participants With Any Post-Treatment Infection | 14.3 (4.20 to 24.37) | 9.5 (3.51 to 15.47) |
SARS-CoV-2 virus RNA will be measured by reverse-transcriptase quantitative polymerase chain reaction (RT-qPCR)
| log10 copies/mL | Placebo | RO7496998 (AT-527) |
|---|---|---|
| Baseline | 6.49 ± 1.61 | 6.59 ± 1.54 |
| Day 3 | -1.05 ± 1.06 | -1.07 ± 1.16 |
| Day 5 | -2.24 ± 1.40 | -2.01 ± 1.50 |
| Day 7 | -3.10 ± 1.38 | -2.98 ± 1.66 |
| Day 14 | -4.21 ± 1.64 | -4.25 ± 1.64 |
Defined as time from randomization to the first time when a negative qualitative virus RNA by RT-PCR test result is obtained.
| days | Placebo | RO7496998 (AT-527) |
|---|---|---|
| Time to Cessation of SARS-CoV-2 Viral Shedding | 13.0 (12.8 to NA) | 13.0 (13.0 to 13.1) |
Defined as percentage of participants with a positive qualitative virus RNA by RT-PCR.
| percentage of participants | Placebo | RO7496998 (AT-527) |
|---|---|---|
| Baseline | 97.1 | 100 |
| Day 3 | 98.5 | 96.4 |
| Day 5 | 89.7 | 91.9 |
| Day 7 | 74.6 | 76.3 |
| Day 14 | 43.9 | 34.4 |
| log10 copies/mL*hour | Placebo | RO7496998 (AT-527) |
|---|---|---|
| Area Under the Curve (AUC) in the Amount of SARS-CoV-2 Virus RNA | 1122.39 ± 339.70 | 1174.30 ± 377.49 |
| percentage of participants | Placebo | RO7496998 (AT-527) |
|---|---|---|
| Percentage of Participants With Adverse Events (AEs) | 36.6 | 39.0 |
AT-511 is the free base form of RO7496998 (AT-527).
| nanograms per milliliter (ng/mL) | RO7496998 (AT-527) |
|---|---|
| Day 1, 0 hour | 17.4 ± 158.6 |
| Day 1, 1 hour | 1456.8 ± 1757.7 |
| Day 1, 2 hours | 1029.3 ± 1085.5 |
| Day 1, 4 hours | 206.3 ± 289.5 |
| Day 5, 0 hour | 52.8 ± 271.0 |
| Day 5, 1 hour | 1659.0 ± 2213.9 |
| Day 5, 2 hours | 1934.5 ± 2210.6 |
| Day 5, 4 hours | 202.3 ± 310.7 |
| Day 5, 8 hours | 8.8 ± 9.5 |
| Day 5, 48 hours | 4.6 ± 40.9 |
AT-511 is the free base form of RO7496998 (AT-527). Major metabolites are AT-551, AT-229, and AT-273 (a surrogate for the intracellular concentration of the active triphosphate metabolite AT-9010)
| nanograms per milliliter (ng/mL) | RO7496998 (AT-527) |
|---|---|
| Day 1, 0 hour | 1.9 ± 12.2 |
| Day 1, 1 hour | 166.9 ± 209.8 |
| Day 1, 2 hours | 335.7 ± 257.6 |
| Day 1, 4 hours | 195.0 ± 146.4 |
| Day 5, 0 hour | 49.1 ± 65.0 |
| Day 5, 1 hour | 150.2 ± 144.5 |
| Day 5, 2 hours | 213.6 ± 201.7 |
| Day 5, 4 hours | 138.8 ± 136.2 |
| Day 5, 8 hours | 27.5 ± 17.5 |
| Day 5, 48 hours | 2.6 ± 5.2 |
AT-511 is the free base form of RO7496998 (AT-527). Major metabolites are AT-551, AT-229, and AT-273 (a surrogate for the intracellular concentration of the active triphosphate metabolite AT-9010)
| nanograms per milliliter (ng/mL) | RO7496998 (AT-527) |
|---|---|
| Day 1, 0 hour | 2.2 ± 18.4 |
| Day 1, 1 hour | 123.6 ± 172.5 |
| Day 1, 2 hours | 507.8 ± 497.5 |
| Day 1, 4 hours | 354.4 ± 259.2 |
| Day 5, 0 hour | 367.8 ± 259.1 |
| Day 5, 1 hour | 418.0 ± 257.6 |
| Day 5, 2 hours | 454.3 ± 331.7 |
| Day 5, 4 hours | 490.1 ± 296.4 |
| Day 5, 8 hours | 279.6 ± 176.0 |
| Day 5, 48 hours | 118.7 ± 127.2 |
AT-511 is the free base form of RO7496998 (AT-527). Major metabolites are AT-551, AT-229, and AT-273 (a surrogate for the intracellular concentration of the active triphosphate metabolite AT-9010)
| nanograms per milliliter (ng/mL) | RO7496998 (AT-527) |
|---|---|
| Day 1, 0 hour | 0.7 ± 2.5 |
| Day 1, 1 hour | 15.5 ± 26.9 |
| Day 1, 2 hours | 135.1 ± 136.2 |
| Day 1, 4 hours | 173.5 ± 120.6 |
| Day 5, 0 hour | 149.8 ± 78.1 |
| Day 5, 1 hour | 141.7 ± 72.7 |
| Day 5, 2 hours | 108.8 ± 61.0 |
| Day 5, 4 hours | 172.7 ± 129.2 |
| Day 5, 8 hours | 118.6 ± 80.2 |
| Day 5, 48 hours | 48.4 ± 32.7 |
Collected over up to the Day 33 visit. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/71 (0%) | 7/71 (9.9%) | 5/71 (7%) |
| AT-527 | 0/141 (0%) | 5/141 (3.5%) | 11/141 (7.8%) |
| Event | Placebo | AT-527 |
|---|---|---|
| COVID-19 pneumoniaInfections and infestations | 4/71 | 1/141 |
| COVID-19Infections and infestations | 3/71 | 2/141 |
| Pneumonia staphylococcalInfections and infestations | 0/71 | 1/141 |
| Acute kidney injuryRenal and urinary disorders | 0/71 | 1/141 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/71 | 1/141 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 0/71 | 1/141 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/71 | 1/141 |
| Event | Placebo | AT-527 |
|---|---|---|
| HeadacheNervous system disorders | 5/71 | 4/141 |
| Back painMusculoskeletal and connective tissue disorders | 0/71 | 8/141 |
| Age, Continuous(years) | Placebo | RO7496998 (AT-527) | Total |
|---|---|---|---|
| Mean | 41.7 ± 14.9 | 41.1 ± 13.2 | 41.3 ± 13.7 |
| Sex: Female, Male(Participants) | Placebo | RO7496998 (AT-527) | Total |
|---|---|---|---|
| Female | 32 | 62 | 94 |
| Male | 41 | 81 | 122 |
| Race (NIH/OMB)(Participants) | Placebo | RO7496998 (AT-527) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 6 | 9 | 15 |
| Asian | 14 | 26 | 40 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 1 | 3 | 4 |
| White | 50 | 105 | 155 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Number of COVID-19 Symptoms Present at Baseline(Number of Covid-19 Symptoms) | Placebo | RO7496998 (AT-527) | Total |
|---|---|---|---|
| Mean | 7.85 ± 2.58 | 7.92 ± 2.74 | 7.90 ± 2.68 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm)
Ran from Apr 2021 to primary completion in Dec 2021, 7 months.
Results were first posted in Jan 2024, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AT-511